Abstract 1404P
Background
Combination of anti-PD1 inhibitor with chemoradiotherapy (CRT) has been shown to improve the survival of patients with locally advanced esophageal squamous cell carcinoma (ESCC). This study specifically aims to identify circulating cytokines as biomarkers for predicting treatment response, survival, and immune-related toxicities.
Methods
Patients with locally advanced ESCC from two phase II clinical trials (EC-CRT-001 and NEOCRTEC1901) were pooled for analysis. All patients received CRT in combination with toripalimab, an anti-PD1 inhibitor. We longitudinally profiled 19 cytokines in the plasma before (pre), during, and after (post) CRT. The associations between cytokine levels and treatment response or immune-related toxicity were examined using the Wilcoxon test. Their correlations with overall survival (OS) and progression-free survival (PFS) were assessed through univariate and multivariate Cox analyses.
Results
A total of 81 patients were included, and 243 plasma samples were analyzed. Multivariate analyses indicated that pre-treatment levels of IL-8 and post-treatment levels of Granzyme B were independent prognostic markers for OS (p<0.05). Post-CRT levels of IL-10 were identified as independent prognostic markers for PFS (p<0.05). Subgroup analyses revealed correlations between pre- and during-CRT levels of IL-8, and post-CRT levels of IL-13 and IL-10 with a complete clinical response in the EC-CRT-001 group. Additionally, pre-CRT IL-8 and post-CRT CCL5 levels were associated with immune-related toxicities.
Conclusions
Circulating cytokines, particularly IL-8, serve as significant biomarkers for predicting response, survival, and immune-related toxicities in locally advanced ESCC patients undergoing combined chemoradiotherapy and toripalimab treatment.
Clinical trial identification
NCT04005170; NCT04006041.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1417P - Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons
Presenter: Elizabeth Smyth
Session: Poster session 17
1418P - Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial
Presenter: Manavi Sachdeva
Session: Poster session 17
1419P - Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G/GEJ cancer (TranStar102)
Presenter: Lin Shen
Session: Poster session 17
1420P - Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Presenter: Seiya Sato
Session: Poster session 17
1421P - Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)
Presenter: Joshua Tobias
Session: Poster session 17
1422P - First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2–) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2
Presenter: Fernando Rivera Herrero
Session: Poster session 17
1423P - Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
Presenter: Elena Elimova
Session: Poster session 17
1424P - Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial
Presenter: Anderley Gordon
Session: Poster session 17
1426P - BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Liu Chang
Session: Poster session 17